Skip to main content

Month: February 2021

Innate Pharma to host key opinion leader discussion on the potential role of lacutamab across T-cell lymphomas

Marseille, Feb. 03, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host a virtual key opinion leader (KOL) discussion focused on the potential role of its lead investigational drug candidate, lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody in development for T-cell lymphomas. The event will be held virtually on Tuesday, February 9, 2021 at 2:00 p.m. CET / 8:00 a.m. ET.The event will feature presentations from the Company’s executive leadership team, as well as the following KOLs:Pierluigi Porcu, M.D., Professor of Medical Oncology, Dermatology and Cutaneous Biology and Director, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation at Thomas Jefferson University, US; Principal Investigator...

Continue reading

Innate Pharma organise une conférence avec des experts sur le rôle potentiel de lacutamab dans les lymphomes à cellules T

Marseille, 03 févr. 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris : IPH – ISIN : FR0010331421 ; Nasdaq : IPHA) (« Innate » ou la « Société ») a annoncé aujourd’hui qu’elle organisera une conférence avec des experts sur le rôle potentiel de son candidat médicament expérimental le plus avancé, lacutamab, un anticorps anti-KIR3DL2, en cours de développement dans les lymphomes à cellules T. L’événement virtuel aura lieu le mardi 9 février 2021 à 14h00 CET / 8h00 ET.L’événement comprendra des présentations de l’équipe de management ainsi que des experts suivants :Pierluigi Porcu, Professeur d’oncologie médicale, de dermatologie et de biologie cutanée, Directeur de la division des maladies hématologiques et de transplantation de cellules souches hématopoïétiques de l’Université Thomas Jefferson...

Continue reading

Borregaard ASA: The Board of Directors’ dividend proposal to Borregaard’s Annual General Meeting

3 February 2021: Borregaard ASA (“Borregaard”, OSE ticker: BRG)At a meeting on 2 February 2021 the Board of Directors of Borregaard ASA decided to propose an ordinary dividend for 2020 of NOK 2.50 per share to the Annual General Meeting. Dividend payment is estimated at NOK 249 million. The exact amount will depend on the number of treasury shares held at the date of the Annual General Meeting. No dividend will be paid on treasury shares held by the Borregaard Group.Provided that the traded shares are subject to ordinary settlement in the Norwegian Securities Register (VPS), shares acquired up to and including 14 April 2021 will carry the right to receive dividends, whereas shares that are acquired on and after 15 April 2021 will not carry the right to receive dividends. Subject to the decision of the Annual General Meeting, the dividend...

Continue reading

SIKA EXTENDS PRODUCT PORTFOLIO FOR SWEDEN’S MINING INDUSTRY

SIKA EXTENDS PRODUCT PORTFOLIO FOR SWEDEN’S MINING INDUSTRYSika has further expanded additive production for shotcrete at Spånga, near Stockholm in Sweden, and upscaled to the latest-generation technology. The new process makes it possible to deliver tailored solutions in demanding projects for customers. The primary customer of the set accelerator marketed under the Sigunit® brand is the mining industry, for which a high level of early strength development and maximum safety in shotcrete application is key.Ivo Schädler, Regional Manager EMEA: “The new technology allows us to offer reliable shotcrete solutions that are tailored to customer requirements in the best possible way. Our customers include leading mining companies that sign long-term supply agreements with us. The potential for growth is not limited to Sweden alone,...

Continue reading

Ringkjøbing Landbobank’s annual report for 2020

Nasdaq CopenhagenLondon Stock ExchangeOther stakeholders3 February 2021Ringkjøbing Landbobank’s annual report for 2020The bank’s board of directors and general management today approved the annual report for 2020.In March 2020 we downwardly adjusted our expectations for net profit for the year as a result of the coronavirus pandemic. During the year we have built up large management reserves for handling of any later impairment charges. However, the bank’s core income was not negatively affected as we had expected in March. We therefore upwardly adjusted our expectations in October. The 2020 profit before tax was realised at the upper end of our expectations.Core earnings2020 – highlightsOur main focus during the coronavirus pandemic has been to help our customers and business partners – and of course to ensure safe working conditions...

Continue reading

Ringkjøbing Landbobanks årsrapport for 2020

Nasdaq CopenhagenLondon Stock ExchangeØvrige interessenter3. februar 2021Ringkjøbing Landbobanks årsrapport for 2020Bankens bestyrelse og direktion har i dag godkendt årsrapporten for 2020.Vi nedjusterede i marts 2020 vores forventninger til årets resultat på grund af Corona-pandemien. I løbet af året har vi opbygget store ledelsesmæssige reserver til at håndtere eventuelle senere nedskrivninger. Bankens basisindtægter blev imidlertid ikke negativt påvirkede, som vi forventede i marts, hvorfor vi i oktober igen opjusterede forventningerne. Resultatet før skat for 2020 blev realiseret helt i toppen af forventningerne.BasisresultatÅret 2020 i overskrifterVores hovedfokus under Corona-pandemien har været og er fortsat at hjælpe vores kunder og samarbejdspartnere – og selvfølgelig at have sikre arbejdsforhold for vores medarbejdereResultat...

Continue reading

Melexis announces changes to Board of Directors and Management

Press release – Inside Information – Regulated InformationIntermediate declaration by the Board of DirectorsIeper, Belgium – February 3rd, 2021, 07.00 hrs CETDear,Please find herewith the link to our most recent press release:https://www.melexis.com/en/news/2021/3feb2021-melexis-announces-changes-to-board-of-directors-and-managementAttachmentPR_ENG_Melexis_Changes in Board of Directors and Management

Continue reading

Melexis kondigt veranderingen aan in raad van bestuur en management

Persbericht – Voorwetenschap – Gereglementeerde informatieTussentijdse verklaring, opgesteld door de Raad van BestuurIeper, België – 3 februari 2021, 07.00 uur CETGeachte,hieronder vindt u de link naar ons meest recente persbericht:https://www.melexis.com/nl/news/2021/3feb2021-melexis-announces-changes-to-board-of-directors-and-managementBijlagePR_NL_Melexis_Changes in Board of Directors and Management

Continue reading

Melexis annonce des changements dans son conseil d’administration et sa direction

Communiqué de presse – Information privilégiée – Information réglementéeMelexis annonce des changements dans son conseil d’administration etsa directionYpres, Belgique – le 3 février 2021, 07.00 H. CETVeuillez trouver ici le lien vers notre dernier communiqué de presse:https://www.melexis.com/fr/news/2021/3feb2021-melexis-announces-changes-to-board-of-directors-and-managementPièce jointePR_FR_Melexis_Changes in Board of Directors and Management

Continue reading

Borregaard ASA: EBITDA of NOK 263 million in the 4th quarter

Borregaard’s operating revenues increased to NOK 1,338 million (NOK 1,234 million)¹ in the 4th quarter of 2020. EBITDA² increased to NOK 263 million (NOK 183 million). All business areas improved their result compared with the corresponding quarter in 2019. The total net currency impact on EBITDA was slightly negative compared with the 4th quarter of 2019.In BioSolutions, EBITDA increased due to improved product mix for biopolymers and lower operating expenses. BioMaterials had lower wood and energy costs and high deliveries compared with the weak result in the 4th quarter of 2019, which was impacted by operational incidents at the Sarpsborg site. A favourable product mix for pharma intermediates and higher sales volume for bioethanol were the main reasons for an improved result in Fine Chemicals.Other income and expenses were NOK -20...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.